RxDoctor Payments Data

Hiva Bastanmehr, MD

Internal Medicine · Rolling Hills Estates, CANPI 1396751194

Payments from drug & device makers

$1,314in general payments, 2019–2025

Across 42 payments — averaging $31.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$287
  • GSK$257
  • Amgen$209
  • Lilly USA, LLC$130
  • AbbVie$78
  • Pfizer$68
  • plus $286 from 8 others

What the payments were for

  • Food & beverage$1,314100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,314 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$116,595
Medicare patients
256
Services billed
989

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$88,741
EliquisApixaban40$34,970
TradjentaLinagliptin21$23,162
XareltoRivaroxaban11$16,545
MyrbetriqMirabegron12$15,267
RybelsusSemaglutide12$14,388
SynthroidLevothyroxine Sodium44$4,921
Rosuvastatin Calcium257$3,915
Atorvastatin Calcium390$3,420
Losartan Potassium251$2,418
Metoprolol Succinate154$2,176
Levothyroxine Sodium213$2,001
Wixela InhubFluticasone Propion/Salmeterol13$1,693
Amlodipine Besylate242$1,255
Olmesartan Medoxomil31$1,102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$45$103,128105 claims
PfizerEliquis$68$34,97040 claims
Boehringer IngelheimTradjenta$51$23,16221 claims
AbbVieSynthroid$78$4,92144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Rolling Hills Estates

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →